Product and Process for Mucus Viscosity Normalization
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 61/792,198, filed Mar 15, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,168,290 | Product and Process for Mucus Viscosity Normalization In force · High confidence UsedRemaining | Orpro Therapeutics, Inc. | In force | High confidence | ||
| US 12,390,511 | Product and Process for Mucus Viscosity Normalization In force · High confidence | Orpro Therapeutics, Inc. | In force | High confidence | ||
| Application 14/852,113 | Product and Process for Mucus Viscosity Normalization Abandoned Abandoned Mar 31, 2021 | Orpro Therapeutics, Inc. | Abandoned | Abandoned Mar 31, 2021 | ||
| Application 19/292,329 | Product and Process for Mucus Viscosity Normalization Pending Not granted | Orpro Therapeutics, Inc. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Orpro Therapeutics, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.